NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer's Treatment
Summary
NeuroEM Therapeutics closed initial rounds of a $5 million equity raise, securing $1.33 million so far from BlueLake.vc. The company will use the capital to advance commercialization of its Transcranial Electromagnetic Treatment (TEMT-RF) for Alzheimer's and other neurodegenerative diseases. NeuroEM says its first commercial product is a lightweight at-home cap now in development and backed by early clinical and preclinical results. BlueLake partner Jamie Rutledge also joined NeuroEM’s board to help guide the company toward clinical, regulatory, and commercial milestones.
Funding
Amount
$1.3M
Total raised
Date
June 13, 2025
Announcement date
Investors
U.S. Food and Drug Administration, StartUp Health
Lead investors
Company
neuroem.com
Funded company
Classifications
industries
Fintech & Banking
applications
No applications detected
AskAI Classifications
Labels
Medical Software
Healthcare Technology
SaaS
Linked Companies
NeuroEM Therapeutics, Inc.
up to $1M